A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 425-430

  Stahl, Stephen M ^a,b   Malla, Ashok ^c   Newcomer, John W ^d   Potkin, Steven G ^e   Weiden, Peter J ^f   Harvey, Philip D ^g   Loebel, Antony ^h   Watsky, Eric ^h   Siu, Cynthia O ⁱ   Romano, Steve ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PFIZER INC   (United States)

ⁱ Data Power Inc   (United States)

Author keywords

functional recovery; haloperidol; long term negative symptom efficacy; remission; ziprasidone

Indexed keywords

HALOPERIDOL; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEGATIVE SYNDROME; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; DOSE RESPONSE; FOLLOW UP; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA; TIME;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955176471     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e69042     Document Type: Article

References (17)

1. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115:93-200.
2. Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495-506.
3. Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
4. Cassidy CM, Ross N, Manchanda R, et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2009; doi: 10.1093/schbul/sbp007.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
6. Murphy BP, Chung Y-C, Park T-W, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88:5-25.
7. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
8. Carpenter WT Jr, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 1995;152:827-832.
9. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res. 1990;3:127-129.
10. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115:4-11.
11. Robinson DG, Woerner MG, McMeninam M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
12. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
13. Potkin SG, Weiden P, Loebel AD, et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacology. 2009;12:1233-1248.
14. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality-of-Life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
15. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65:1624-1633.
16. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492-1495.
17. Suissa S. Calculation of number needed to treat. N Engl J Med. 2009;361:424.